e-Drug3D

1949

UBROGEPANT

INN
UBROGEPANT

cas 1374248-77-7

CLASS

NERVOUS SYSTEM
CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONIST
TREATMENT OF MIGRAINE

ROUTE (list)

ORAL

ATC code

N02CD04

PK parameters

Tmax 1.5 HOUR
VD 350 LITER
Cl 87 LITER / HOUR
PPB 87 PERCENT
t1/2 6 HOUR

Solubility

PRACTICALLY INSOLUBLE IN WATER

Target

TARGET CALCITONIN GENE-RELATED PEPTIDE (CGRP) RECEPTOR

DrugCentral

Calcitonin gene-related peptide type 1 receptor UNIPROT Q16602 CALCRL

Download SDF file

Spiro[6H-cyclopenta[b]pyridine-6,3'-[3H]pyrrolo[2,3-b]pyridine]-3-carboxamide, 1',2',5,7-tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2'-oxo-, (3'S)-

Formula:
C29H26F3N5O3

Calculated chemical properties:

MW 549.55
NB_atoms 40
XLogP 3.53
PSA 95.074
NB_HD 2
NB_HA 8
fsp3 0.34
Lipinski(0=no;1=yes) 0

FDA
NDA 211765 (label) INN (UBROGEPANT) UBRELVY (ABBVIE) APPROVAL= AP YEAR= 2019 NEWMOLECULARENTITY
NDA 219088 (pdf not found) INN (UBROGEPANT) UBROGEPANT (AUROBINDO PHARMA LIMITED) APPROVAL= TA YEAR= 2025